The detection and staging of prostate cancer (PCa) dramatically improved over the last decade due to wide introduction into the clinical practice of prostate-specific membrane antigen (PSMA)-targeting agents based on Glu-urea-Lys binding moiety. The gene discussed is FOLH1; the disease is posterior cortical atrophy.